The median time to first treatment was shorter in patients with IgM U-CLL (54.03 months) compared with patients with IgM M-CLL (166.73 months) or IgG M-CLL (187.63 months), p = 0.0002 (Figure 1C). This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.